Nucleic acid payload

Nucleic acid payloads represent the functional genetic components of gene therapy, encompassing molecules such as plasmid DNA (pDNA), messenger RNA (mRNA), and small interfering RNA (siRNA). When carried by poly(beta-amino ester) (PBAE) polymers, these payloads are formulated into nanoparticles designed for efficient intracellular delivery and endosomal escape (Green et al., 2008, Accounts of Chemical Research). PBAEs are particularly valued in the biotech industry for their high transfection efficiency, ease of synthesis, and biodegradable nature, which minimizes long-term toxicity compared to other cationic carriers (Eltoukhy et al., 2012, Biomaterials). The biological role of the payload is determined by its sequence, acting either to restore protein function through gene addition or to downregulate disease-associated proteins through RNA interference (Tzeng & Green, 2013, Advanced Healthcare Materials). This modality is currently being explored for diverse applications, including oncology, where it can deliver suicide genes or immunostimulatory signals directly to the tumor microenvironment (Mangraviti et al., 2016, ACS Nano). Once internalized, the payload is released into the cytoplasm or nucleus, where it utilizes the host cell's machinery to exert its therapeutic effect (Kim, J., et al., 2014, Progress in Polymer Science). Safety considerations primarily involve the potential for innate immune responses to the nucleic acid and the biocompatibility of the polymer carrier. This technology offers a versatile platform for non-viral gene therapy, providing a safer and more scalable alternative to viral vectors.

Other names

Genetic cargoTherapeutic nucleic acidPolynucleotide payloadPBAE-nucleic acid complex

The mechanism involves the delivery of genetic material into target cells where it either undergoes translation to produce a functional protein or utilizes the RNA-induced silencing complex (RISC) to degrade specific mRNA targets.